Your browser doesn't support javascript.
loading
Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients.
Eltahir, M; Fletcher, E; Dynesius, L; Jarblad, J L; Lord, M; Laurén, I; Zekarias, M; Yu, X; Cragg, M S; Hammarström, C; Levedahl, K H; Höglund, M; Ullenhag, G; Mattsson, M; Mangsbo, S M.
Afiliación
  • Eltahir M; Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Fletcher E; Immuneed AB, Uppsala, Sweden.
  • Dynesius L; Immuneed AB, Uppsala, Sweden.
  • Jarblad JL; Immuneed AB, Uppsala, Sweden.
  • Lord M; Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Laurén I; Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Zekarias M; Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Yu X; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, UK.
  • Cragg MS; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, UK.
  • Hammarström C; Clinical Trial Consultants AB, Uppsala, Sweden.
  • Levedahl KH; Department of Haematology, Uppsala University Hospital; Department of Public Health and Caring Sciences, Uppsala University, Sweden.
  • Höglund M; Department of Haematology, Uppsala University Hospital.
  • Ullenhag G; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Mattsson M; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Haematology, Uppsala University Hospital.
  • Mangsbo SM; Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Electronic address: sara.mangsbo@farmbio.uu.se.
Int Immunopharmacol ; 90: 107226, 2021 Jan.
Article en En | MEDLINE | ID: mdl-33316742
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Rituximab / Antineoplásicos Inmunológicos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Rituximab / Antineoplásicos Inmunológicos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Suecia